Dipeptidyl Peptidase IV Inhibitors Market Share, Growth, and Forecast to 2025Posted by rekha on October 16th, 2019 The global dipeptidyl peptidase IV inhibitors market was valued at US$ XX Mn in 2018 and increasing at a prominent growth rate over the forecast years due to increase in the prevalence of diabetes around the globe. For instance, according to International Diabetes Foundation 2017, approximately 425 Mn adults were living with diabetes and this will expected to reach 629 Mn by 2045. Moreover, grow in geriatric population, increase in the R&D expenditure for the development of newer drugs, pipeline drugs under various stages of clinical trials, and rise in healthcare expenditure are propel the global dipeptidyl peptidase IV inhibitors market over the forecast years. However, patent expiry of block buster drugs, high cost of drugs, and entry of Biosimilars into market are hamper the growth of DPP IV inhibitors market over the forecast timeframe Global Dipeptidyl Peptidase IV Inhibitors market segmented on the basis of drug type, distribution channel, and region For request sample: https://www.precisionbusinessinsights.com/request-sample?product_id=15837 Sitagliptin Dominated the Global Dipeptidyl Peptidase IV Inhibitors Market Based on the drug class, global dipeptidyl peptidase IV inhibitors market segmented into Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, and others. Among all the drugs, Sitagliptin dominated the global dipeptidyl peptidase IV inhibitors market owing to safety of the drug in patients with cardiac diseases. Moreover, Linagliptin revenue is growing at tremendous growth rate over the forecast years owing to safety for the patients with neuropathic disorders and launch of combination drugs such as Linagiptin with Empagliflozin. North America Leads the Global Dipeptidyl Peptidase IV Inhibitors market PBI’s global dipeptidyl peptidase IV inhibitors market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. According to regional analysis, North America accounted for larger revenue share through 2014-2018 and expected to dominate over 2019-2025 owing to surge in the prevalence of diabetes in U.S. and Canada. For instance, according to CDC 2015, approximately 30 Mn Americans have diabetes and another 84 Mn have prediabetes that may leads to type 2 diabetes within 5 years if they are not treated. Moreover, favorable reimbursement policies, increase in the R&D activities for the development of newer therapeutics, and better availability of the products are bolster the market over the forecast years. Europe dipeptidyl peptidase IV inhibitors market projected to exhibit significant growth due to rise in rise in aging population and change in food habits in the region. For instance, according to Eurostat 2015, approximately 1/5th of overall population in Europe are over 65 years is expected to bolster the market. Launch of newer products, frequent product approvals, and strategic alliances are the key strategies adopted by market players Global dipeptidyl peptidase IV inhibitors market further reveals that the key players increasingly adopting strategies such as launch of newer products, frequent product approvals, and long term alliance to improve market revenue share and gaining significant geographic presence across the region. For instance. In July 2018, Boehringer Ingelheim India and Lupin collaborated to market two new oral anti-diabetics Gibtulio Met®(Empagliflozin + Metformin) and Ajaduo® (Empagliflozin + Linagliptin), approved by the Drugs Controller General of India (DCGI) Key player’s profiles in the report are Merck & Co. Inc. Novartis AG, Sanofi S.A. Takeda Pharmaceuticals, Boehringer Ingelheim GmbH, Eli Lilly & Co., and Others Precision Business Insights (PBI) in its report titled “Global Dipeptidyl Peptidase IV Inhibitors Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2025” assesses the market performance over seven years forecast period over 2019-2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period. Detailed Segmentation By Drug Type o Sitagliptin o Vildagliptin o Saxagliptin o Linagliptin o Others By Distribution Channel o Hospital Pharmacies o Retail Pharmacies o Online Pharmacies Geography o North America
o Europe
o Asia-Pacific
o Latin America
o Middle East and Africa (MEA)
For more information: https://www.precisionbusinessinsights.com/market-reports/global-dipeptidyl-peptidase-iv-dpp-iv-inhibitors-market/ Like it? Share it! More by this author |